Evaluation of the Suitability of PD P 506 A in the PDT of Distal Subungual Onychomycosis (DSO) of the Great Toenail.

Evaluation of the Suitability of PD P 506 A in the Photodynamic Therapy of Distal Subungual Onychomycosis (DSO) of the Great Toenail.

This study evaluates the potential usefulness of photodynamic therapy with PD P 506 A in patients with distal subungual onychomycosis of the great toenail. Patients will receive four PDT treatments with PD P 506 A in weekly intervals.

Study Overview

• Status: Completed
• Conditions: Onychomycosis
• Intervention / Treatment: Drug: PD P 506 A

• Study Type: Interventional
• Enrollment (Actual): 25
• Phase: Phase 2

Contacts and Locations

Study Locations

• Germany
  • Detmold, Germany, 32756
    • Klinik für Dermatologie, Klinikum Lippe
  • Recklinghausen, Germany, 45657
    • Klinik für Dermatologie und Allergologie KLINIKUM VEST GMBH Knappschaftskrankenhaus Recklinghausen

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male 18 - 75 years of age
• Females up to an age of 75 years provided that they are postmenopausal, i.e. with spontaneous amenorrhea for at least 12 months or not of childbearing potential because of tubal ligation or hysterectomy
• DSO of at least one of the great toe(s) affecting 20% to 60% of the target nail without spikes, confirmed before Visit 1 by at least one of the three methods: the methods of KOH test, periodic acid-Schiff (PAS) stain and mycology culture
• The toenail infection can be due to a dermatophyte, yeast or mixed infections (dermatophyte and non-dermatophyte)
• Toenails have to be cut regularly (indicator for existing growth)
• Signed written informed consent

Exclusion Criteria:

• Patients with the target toenail involving the matrix (lunula) or having less than 2 mm clear (unaffected) nail plate length beyond the proximal fold
• Presence of dermatophytoma (defined as demarcated and localised thick masses (≥ 3 mm) of fungal hyphae and necrotic keratin between the nail plate and nail bed) on the target nail
• Other conditions than DSO known to cause abnormal nail appearance
• Topical antifungal treatment of the nails within 1 month before PDT
• Systemic use of antifungal treatment within 3 months before PDT
• Patients who are unwilling to provide nail clippings
• Patients who have been previously reported to be allergic against 5-aminolevulinic acid or other ingredients of PD P 506 A
• Diagnosis of porphyria
• Diagnosis of polyneuropathy
• Dementia or psychic condition that might interfere with the ability to understand the study and thus give written informed consent
• Simultaneous participation in another clinical study or participation in another clinical study in the 30 days directly preceding treatment

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PD P 506 A-PDT; One PD P 506 A-patch will be administered to each great toenail for 4 hours. After removal of the study medication the study nail(s) s will be illuminated with red light of defined wavelength (PDT).	Drug: PD P 506 A; PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm².; Other Names: Alacare®

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of nails with Clinically Complete Cure	The Complete Clinical Clearance of each treated nail will be determined 3, 6 and 12 months after last study treatment. Based on a visual inspection, the nail(s) will either be defined as "completely cleared" or "partially" or "not cleared". To be defined as "completely cleared", a nail must show 100% absence of the 4 following clinical signs of onychomycosis (according to Scher et al., J Am Acad Dermatol. 2007 Jun;56(6):939-44): Residual changes of the nail plate compatible with dermatophyte infection; White/yellow or orange brown/patches or streaks in or beneath the nail; Lateral onycholysis with debris in an otherwise clear nail plate; Hyperkeratoses on the lateral nail plate/nailfold edge. If the nail shows an improvement but still one of the above signs, it will be rated as "partially cleared". If the nail shows no improvement in comparison to the Screening Visit, it will be rated as "not cleared".	12 months after last study treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of nails with negative laboratory test results for onychomycosis (KOH test, periodic acid-Schiff (PAS) stain and mycology culture).		12 months after last study treatment
Percentage of nails with Clinically Complete Cure	The Complete Clinical Clearance of each treated nail will be determined 3, 6 and 12 months after last study treatment. Based on a visual inspection, the nail(s) will either be defined as "completely cleared" or "partially" or "not cleared". To be defined as "completely cleared", a nail must show 100% absence of the 4 following clinical signs of onychomycosis (according to Scher et al., J Am Acad Dermatol. 2007 Jun;56(6):939-44): Residual changes of the nail plate compatible with dermatophyte infection; White/yellow or orange brown/patches or streaks in or beneath the nail; Lateral onycholysis with debris in an otherwise clear nail plate; Hyperkeratoses on the lateral nail plate/nailfold edge. If the nail shows an improvement but still one of the above signs, it will be rated as "partially cleared". If the nail shows no improvement in comparison to the Screening Visit, it will be rated as "not cleared".	3 and 6 months after last study treatment
Frequency of adverse events		During the treatment phase on day 0, 7, 14 and 21, and 3, 6 and 12 months after last study treatment
Severity (grade1-5) of adverse events	The severity of AEs is defined as: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = fatal	During the treatment phase on day 0, 7, 14 and 21, and 3, 6 and 12 months after last study treatment
Frequency of local reactions.	Photodynamic therapy is intended to produce a phototoxic reaction, which is part of the desired effect. After PDT, treated toes may show local reactions such as redness and swelling.	During the treatment phase on day 0, 7, 14 and 21, and 3, 6 and 12 months after last study treatment
Severity (grade1-3) of local reactions.	The severity of local reactions is defined as: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe	During the treatment phase on day 0, 7, 14 and 21, and 3, 6 and 12 months after last study treatment
One photo of each treated toenail at the beginning of each visit	Documentation of the course of the study for each treated toenail.	At screening visit (up to 4 weeks before first treatment), during the treatment phase on day 0, 7, 14 and 21, and 3, 6 and 12 months after last study treatment.

Collaborators and Investigators

• Sponsor: photonamic GmbH & Co. KG
• Investigators: Principal Investigator: Rolf-Markus Szeimies, Prof. Dr., KLINIKUM VEST GMBH Knappschaftskrankenhaus Recklinghausen

Study record dates

Study Major Dates

• Study Start: January 1, 2015
• Primary Completion (Actual): August 23, 2017
• Study Completion (Actual): August 23, 2017

Study Registration Dates

• First Submitted: January 22, 2015
• First Submitted That Met QC Criteria: January 30, 2015
• First Posted (Estimate): February 4, 2015

Study Record Updates

• Last Update Posted (Actual): September 19, 2017
• Last Update Submitted That Met QC Criteria: September 18, 2017
• Last Verified: September 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Infections; Bacterial Infections and Mycoses; Skin Diseases, Infectious; Mycoses; Tinea; Dermatomycoses; Nail Diseases; Onychomycosis
• Other Study ID Numbers: OM 01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No